BIOGEN INC (BIIB)
US09062X1037 - Common Stock
Overall BIIB gets a fundamental rating of 5 out of 10. We evaluated BIIB against 565 industry peers in the Biotechnology industry. While BIIB belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. BIIB is valued quite cheap, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
BIIB had positive earnings in the past year.
In the past year BIIB had a positive cash flow from operations.
In the past 5 years BIIB has always been profitable.
In the past 5 years BIIB always reported a positive cash flow from operatings.
1.2 Ratios
BIIB has a Return On Assets of 5.70%. This is amongst the best in the industry. BIIB outperforms 95.20% of its industry peers.
BIIB has a Return On Equity of 9.87%. This is amongst the best in the industry. BIIB outperforms 95.20% of its industry peers.
BIIB has a Return On Invested Capital of 9.36%. This is amongst the best in the industry. BIIB outperforms 95.55% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BIIB is in line with the industry average of 13.59%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.7% | ||
| ROE | 9.87% | ||
| ROIC | 9.36% |
ROA(3y)7.75%
ROA(5y)12.23%
ROE(3y)14.96%
ROE(5y)25.28%
ROIC(3y)12.12%
ROIC(5y)17.18%
1.3 Margins
BIIB has a Profit Margin of 16.81%. This is amongst the best in the industry. BIIB outperforms 96.44% of its industry peers.
In the last couple of years the Profit Margin of BIIB has declined.
The Operating Margin of BIIB (25.92%) is better than 97.15% of its industry peers.
BIIB's Operating Margin has declined in the last couple of years.
BIIB has a Gross Margin of 75.59%. This is amongst the best in the industry. BIIB outperforms 85.23% of its industry peers.
In the last couple of years the Gross Margin of BIIB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 25.92% | ||
| PM (TTM) | 16.81% | ||
| GM | 75.59% |
OM growth 3Y-15.78%
OM growth 5Y-14.65%
PM growth 3Y-26.52%
PM growth 5Y-18.55%
GM growth 3Y-4.45%
GM growth 5Y-2.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BIIB is still creating some value.
BIIB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BIIB has less shares outstanding
The debt/assets ratio for BIIB is higher compared to a year ago.
2.2 Solvency
BIIB has an Altman-Z score of 2.70. This is not the best score and indicates that BIIB is in the grey zone with still only limited risk for bankruptcy at the moment.
BIIB has a Altman-Z score of 2.70. This is in the better half of the industry: BIIB outperforms 73.84% of its industry peers.
BIIB has a debt to FCF ratio of 3.56. This is a good value and a sign of high solvency as BIIB would need 3.56 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.56, BIIB belongs to the top of the industry, outperforming 94.31% of the companies in the same industry.
A Debt/Equity ratio of 0.28 indicates that BIIB is not too dependend on debt financing.
The Debt to Equity ratio of BIIB (0.28) is worse than 69.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 3.56 | ||
| Altman-Z | 2.7 |
ROIC/WACC0.9
WACC10.41%
2.3 Liquidity
BIIB has a Current Ratio of 1.26. This is a normal value and indicates that BIIB is financially healthy and should not expect problems in meeting its short term obligations.
BIIB has a Current ratio of 1.26. This is amonst the worse of the industry: BIIB underperforms 83.81% of its industry peers.
BIIB has a Quick Ratio of 1.26. This is a bad value and indicates that BIIB is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of BIIB (0.80) is worse than 89.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.8 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 3.16% over the past year.
The earnings per share for BIIB have been decreasing by -10.49% on average. This is quite bad
Looking at the last year, BIIB shows a decrease in Revenue. The Revenue has decreased by -3.86% in the last year.
Measured over the past years, BIIB shows a decrease in Revenue. The Revenue has been decreasing by -6.07% on average per year.
EPS 1Y (TTM)3.16%
EPS 3Y-22.83%
EPS 5Y-10.49%
EPS Q2Q%-6.42%
Revenue 1Y (TTM)-3.86%
Revenue growth 3Y-9.9%
Revenue growth 5Y-6.07%
Sales Q2Q%-2.54%
3.2 Future
Based on estimates for the next years, BIIB will show a small growth in Earnings Per Share. The EPS will grow by 6.48% on average per year.
The Revenue is expected to grow by 0.59% on average over the next years.
EPS Next Y10.84%
EPS Next 2Y6.36%
EPS Next 3Y6.36%
EPS Next 5Y6.48%
Revenue Next Year-2.91%
Revenue Next 2Y-2%
Revenue Next 3Y-0.63%
Revenue Next 5Y0.59%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 8.97, the valuation of BIIB can be described as very reasonable.
BIIB's Price/Earnings ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.86% of the companies in the same industry.
BIIB is valuated cheaply when we compare the Price/Earnings ratio to 27.20, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 8.59, which indicates a very decent valuation of BIIB.
Based on the Price/Forward Earnings ratio, BIIB is valued cheaper than 98.22% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.73, BIIB is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.97 | ||
| Fwd PE | 8.59 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, BIIB is valued cheaply inside the industry as 98.22% of the companies are valued more expensively.
BIIB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.07 | ||
| EV/EBITDA | 8.31 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.83
PEG (5Y)N/A
EPS Next 2Y6.36%
EPS Next 3Y6.36%
5. Dividend
5.1 Amount
BIIB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOGEN INC
NASDAQ:BIIB (12/20/2024, 8:00:01 PM)
After market: 145.698 -0.77 (-0.53%)146.47
-0.92 (-0.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.13%
Inst Owner Change0.02%
Ins Owners0.13%
Ins Owner Change-3.32%
Market Cap21.34B
Analysts77.67
Price Target254.44 (73.71%)
Short Float %1.88%
Short Ratio1.83
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.05%
Min EPS beat(2)5.5%
Max EPS beat(2)28.61%
EPS beat(4)4
Avg EPS beat(4)10.01%
Min EPS beat(4)1.62%
Max EPS beat(4)28.61%
EPS beat(8)8
Avg EPS beat(8)8.49%
EPS beat(12)10
Avg EPS beat(12)8.67%
EPS beat(16)13
Avg EPS beat(16)8.57%
Revenue beat(2)1
Avg Revenue beat(2)0.4%
Min Revenue beat(2)-0.68%
Max Revenue beat(2)1.48%
Revenue beat(4)1
Avg Revenue beat(4)-1.79%
Min Revenue beat(4)-5.08%
Max Revenue beat(4)1.48%
Revenue beat(8)5
Avg Revenue beat(8)0.42%
Revenue beat(12)7
Avg Revenue beat(12)0.61%
Revenue beat(16)9
Avg Revenue beat(16)0.82%
PT rev (1m)-5%
PT rev (3m)-7.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-14.65%
EPS NY rev (1m)-0.12%
EPS NY rev (3m)1.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.78%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.02%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.97 | ||
| Fwd PE | 8.59 | ||
| P/S | 2.22 | ||
| P/FCF | 12.07 | ||
| P/OCF | 10.03 | ||
| P/B | 1.3 | ||
| P/tB | 315.73 | ||
| EV/EBITDA | 8.31 |
EPS(TTM)16.33
EY11.15%
EPS(NY)17.06
Fwd EY11.65%
FCF(TTM)12.14
FCFY8.29%
OCF(TTM)14.6
OCFY9.97%
SpS65.93
BVpS112.26
TBVpS0.46
PEG (NY)0.83
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.7% | ||
| ROE | 9.87% | ||
| ROCE | 10.88% | ||
| ROIC | 9.36% | ||
| ROICexc | 10.11% | ||
| ROICexgc | 43.72% | ||
| OM | 25.92% | ||
| PM (TTM) | 16.81% | ||
| GM | 75.59% | ||
| FCFM | 18.41% |
ROA(3y)7.75%
ROA(5y)12.23%
ROE(3y)14.96%
ROE(5y)25.28%
ROIC(3y)12.12%
ROIC(5y)17.18%
ROICexc(3y)14.77%
ROICexc(5y)20.81%
ROICexgc(3y)31.37%
ROICexgc(5y)43%
ROCE(3y)14.1%
ROCE(5y)19.98%
ROICexcg growth 3Y-19.11%
ROICexcg growth 5Y-16.33%
ROICexc growth 3Y-29.06%
ROICexc growth 5Y-22.85%
OM growth 3Y-15.78%
OM growth 5Y-14.65%
PM growth 3Y-26.52%
PM growth 5Y-18.55%
GM growth 3Y-4.45%
GM growth 5Y-2.68%
F-Score6
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 3.56 | ||
| Debt/EBITDA | 1.46 | ||
| Cap/Depr | 57% | ||
| Cap/Sales | 3.73% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 68.18% | ||
| Profit Quality | 109.49% | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 0.8 | ||
| Altman-Z | 2.7 |
F-Score6
WACC10.41%
ROIC/WACC0.9
Cap/Depr(3y)56.77%
Cap/Depr(5y)77.88%
Cap/Sales(3y)2.75%
Cap/Sales(5y)3.4%
Profit Quality(3y)119.62%
Profit Quality(5y)111.92%
High Growth Momentum
Growth
EPS 1Y (TTM)3.16%
EPS 3Y-22.83%
EPS 5Y-10.49%
EPS Q2Q%-6.42%
EPS Next Y10.84%
EPS Next 2Y6.36%
EPS Next 3Y6.36%
EPS Next 5Y6.48%
Revenue 1Y (TTM)-3.86%
Revenue growth 3Y-9.9%
Revenue growth 5Y-6.07%
Sales Q2Q%-2.54%
Revenue Next Year-2.91%
Revenue Next 2Y-2%
Revenue Next 3Y-0.63%
Revenue Next 5Y0.59%
EBIT growth 1Y3.07%
EBIT growth 3Y-24.11%
EBIT growth 5Y-19.83%
EBIT Next Year37.77%
EBIT Next 3Y12.93%
EBIT Next 5Y16.52%
FCF growth 1Y-18.63%
FCF growth 3Y-30.48%
FCF growth 5Y-25.27%
OCF growth 1Y-11.28%
OCF growth 3Y-28.48%
OCF growth 5Y-24.21%